Toxicology — Salicylate Overdose

• Uncoupling of oxidative phosphorylation: Salicylates act as mitochondrial uncouplers by facilitating proton transport across the inner mitochondrial membrane independent of ATP synthase. This dissipates the proton gradient, causing energy release as heat rather than ATP synthesis. Clinically, this drives hyperthermia and increased oxygen consumption. The body attempts compensation by increasing ventilation, paradoxically worsening the acid-base disturbance.

• Inhibition of cellular respiration and metabolic acidosis: Salicylates inhibit cellular enzymes in the citric acid cycle (particularly succinate dehydrogenase) and impair pyruvate oxidation. This forces metabolism toward anaerobic pathways, producing lactate and causing lactic acidosis. Simultaneously, salicylates undergo β-oxidation to salicyluric acid and gentisic acid, generating additional organic acids. The combination produces severe metabolic acidosis with elevated anion gap, which is the hallmark laboratory finding.

• Direct stimulation of the respiratory center: Salicylates directly stimulate the medullary respiratory center, causing hyperventilation independent of hypoxemia or hypercapnia. Early in toxicity, this produces respiratory alkalosis via excessive CO₂ elimination. This creates a biphasic acid-base disturbance: initial respiratory alkalosis (from central stimulation) followed by metabolic acidosis (from uncoupling and impaired metabolism). The severity of metabolic acidosis often unmasks the respiratory alkalosis, resulting in a mixed picture or predominant acidosis at presentation.

• Salicylate-induced pulmonary edema: Increased capillary permeability, direct lung toxicity from accumulated salicylate, increased pulmonary venous pressure from left ventricular dysfunction, and altered Starling forces all contribute to noncardiogenic pulmonary edema. This occurs in severe cases and represents a major cause of mortality.

• Central nervous system effects: Salicylates cross the blood-brain barrier (particularly when non-ionized at low pH) and directly affect neurons, causing confusion, altered mental status, and seizures. The combination of hyperthermia, acidosis, hypoglycemia (see below), and direct salicylate accumulation in the CNS produces encephalopathy.

• Hypoglycemia: Salicylates uncouple oxidative phosphorylation in all tissues, including pancreatic β-cells, impairing ATP-dependent insulin secretion. Additionally, uncoupling increases glucose utilization peripherally while decreasing hepatic glucose production. This combination produces hypoglycemia, particularly dangerous in the CNS and with concurrent acidosis.

• Altered renal salicylate clearance: Salicylates are renally excreted via glomerular filtration and active tubular secretion. The weak acid nature of salicylates means they are reabsorbed in acidic urine (protonated form crosses tubular epithelium) but excreted in alkaline urine (ionized form cannot be reabsorbed). This has critical therapeutic implications: alkalinization of urine dramatically increases salicylate excretion by ion-trapping, reducing renal reabsorption.

• Platelet dysfunction and bleeding: Salicylates irreversibly acetylate platelet cyclooxygenase (COX), preventing thromboxane A₂ synthesis and impairing platelet aggregation. This produces a prolonged bleeding time and increased bleeding risk.

• Acute intentional overdose (suicide attempt): Adults deliberately ingest large quantities of aspirin or aspirin-containing products. This remains the most common scenario in developed countries for severe salicylate toxicity. Presentation is typically acute (minutes to hours) with rapid symptom progression.

• Chronic accidental overdose from therapeutic use: Patients taking aspirin for chronic pain, cardiac prophylaxis, or rheumatologic conditions gradually accumulate salicylate, especially with renal impairment, dehydration, or concurrent medications affecting renal excretion. This "chronic salicylism" develops insidiously and may present with nonspecific symptoms initially. Elderly patients are at particular risk due to polypharmacy, age-related renal decline, and greater likelihood of therapeutic dosing errors.

• Topical salicylate absorption: Salicylic acid preparations for wart removal, psoriasis, or acne (especially when applied to large body surface areas or under occlusion) and methyl salicylate (oil of wintergreen, liniments, muscle rubs) are readily absorbed through skin. Pediatric cases frequently result from accidental ingestion of topical products or from absorption through intact or damaged skin in young children with thin skin and higher surface area-to-weight ratio.

• Bismuth subsalicylate exposure: Over-the-counter antidiarrheal medications (Pepto-Bismol) contain salicylate. Toxicity typically requires large or repeated ingestions, but cases are documented especially with renal insufficiency or chronic use.

• Predisposing factors to severe toxicity:
• Renal impairment (acute kidney injury, chronic kidney disease): Reduces salicylate clearance dramatically
• Dehydration and volume depletion: Increases renal reabsorption of salicylate and reduces glomerular filtration rate
• Acidemia: Low systemic pH favors salicylate reabsorption in renal tubules
• Concurrent CNS drugs or depressants: Amplify altered mental status
• Pulmonary disease: Increases risk of pulmonary edema
• Age extremes: Neonates and elderly have reduced metabolism and altered pharmacokinetics

• Tinnitus and hearing disturbances: This is a classic early sign, resulting from salicylate effects on the eighth cranial nerve and inner ear. Bilateral high-frequency hearing loss or tinnitus often precedes systemic toxicity and should prompt salicylate screening in the right clinical context.

• Hyperthermia: Hyperthermia is nearly universal in moderate-to-severe toxicity and results from uncoupling of oxidative phosphorylation. Temperature elevation is often disproportionate to the severity of infection (if one is being considered concurrently). Sweating is prominent due to heat dissipation attempts.

• Hyperventilation (tachypnea): Rapid, deep breathing reflects direct medullary stimulation by salicylates. Respiratory rates of 30–40 breaths/minute are common. This physical sign is a major diagnostic clue and precedes altered mental status in typical presentations.

• Altered mental status and encephalopathy: Confusion, agitation, disorientation, and lethargy progress with toxicity severity. Salicylate accumulation in the CNS (especially when systemic acidosis increases non-ionized salicylate crossing the blood-brain barrier), hypoglycemia, hyperthermia, and acidosis all contribute. Severe encephalopathy may progress to obtundation, seizures, or coma.

• Pulmonary edema: Noncardiogenic pulmonary edema develops in severe cases, presenting with dyspnea, orthopnea, rales on lung auscultation, and pink frothy sputum. This is a sign of severe toxicity and major source of mortality. CXR shows bilateral infiltrates without cardiac enlargement.

• Gastrointestinal symptoms: Nausea, vomiting, abdominal pain, and diarrhea are early manifestations from direct gastrointestinal irritation. Salicylates may form bezoars with delayed absorption.

• Acid-base disturbance signs: Kussmaul respirations (deep, labored breathing) develop with significant metabolic acidosis. Mixed respiratory alkalosis and metabolic acidosis may produce variable respiratory patterns.

• Hypoglycemia manifestations: Altered mental status, diaphoresis, tachycardia, and seizures may be partly attributable to concurrent hypoglycemia, particularly in severe cases.

• Bleeding manifestations: Epistaxis, petechiae, or prolonged bleeding from minor wounds reflect salicylate-induced platelet dysfunction. Overt gastrointestinal hemorrhage can occur, especially in chronic toxicity.

• Physical exam findings: Tachycardia, tachypnea (often >30 breaths/min), hypertension or hypotension (depending on severity), hyperthermia, altered mental status, hyperreflexia, and possibly pulmonary rales. In severe cases, signs of shock and multi-organ failure appear.

• Important clinical variants:
• Chronic salicylism: Insidious onset with subtle symptoms (confusion, tinnitus, malaise) in elderly patients on chronic aspirin; often misdiagnosed as dementia, sepsis, or other conditions
• Neonatal salicylate toxicity: Presents with hyperthermia, seizures, and severe acidosis; may be rapidly fatal
• Pulmonary edema predominant: Some cases present primarily with respiratory distress and pulmonary edema without marked CNS symptoms

• Serum salicylate level (most critical diagnostic test): Measured by colorimetric or high-performance liquid chromatography (HPLC) methods. Normal levels are <10 mg/dL. Severity correlates imperfectly with serum level due to variable pharmacokinetics and CNS penetration, but levels >30 mg/dL indicate mild toxicity, 30–60 mg/dL moderate toxicity, >60 mg/dL severe toxicity, and >100 mg/dL often indicates fatal toxicity if untreated. The Done nomogram (plotting serum salicylate level vs. time since ingestion) historically guided prognosis but is no longer recommended as sole criterion since it was derived from old papers and doesn't account for chronic toxicity or individual variation. However, understanding it may appear on board exams: the nomogram suggests toxicity zone vs. expected recovery, with higher levels at any given time indicating worse prognosis.

• Arterial or venous blood gas analysis: Essential for assessing acid-base status. Classic findings include:
• Initial phase: Respiratory alkalosis (pH >7.45, PCO₂ <35 mmHg) from medullary stimulation
• Later phase or severe toxicity: Metabolic acidosis (pH <7.35, HCO₃⁻ <20 mEq/L) from uncoupling and impaired metabolism
• Mixed picture: Both respiratory alkalosis and metabolic acidosis present simultaneously, producing variable pH depending on which predominates
• Elevated anion gap (>12 mEq/L) indicates metabolic acidosis from organic acids (lactate, ketones, salicylate metabolites)

• Electrolyte panel and basic metabolic panel:
• Hypokalemia is common (salicylates cause urinary potassium wasting) and exacerbates metabolic alkalosis and hypoxemia
• Hypoglycemia is documented in 50% of cases; glucose must be checked and monitored
• Elevated BUN and creatinine suggest renal impairment worsening salicylate clearance
• Elevated anion gap confirms metabolic acidosis

• Urine pH and urinalysis: Urine pH should be monitored during treatment; alkaline urine (pH >8) is essential for enhanced salicylate excretion. Urine may show crystalluria or signs of acute tubular necrosis in severe cases.

• Chest X-ray: In suspected severe toxicity, evaluate for noncardiogenic pulmonary edema (bilateral infiltrates, normal cardiac silhouette). Pulmonary edema may develop even in initially stable patients, necessitating serial imaging.

• EKG: Generally nonspecific; may show sinus tachycardia, ST changes with hypokalemia, or arrhythmias in severe toxicity.

• Coagulation studies (PT/INR, PTT, bleeding time): May show prolongation reflecting salicylate-induced platelet dysfunction and impaired hemostasis.

• Diagnostic criteria: Diagnosis requires:

1. 1.Documented or suspected salicylate exposure (history of ingestion or topical application)
2. 2.Serum salicylate level >10 mg/dL (confirmed toxic level) in appropriate clinical context
3. 3.Compatible clinical syndrome (hyperventilation, altered mental status, metabolic acidosis, hyperthermia)
4. 4.Exclusion of alternative diagnoses (sepsis, diabetic ketoacidosis, methanol/ethylene glycol poisoning)

• Differential diagnosis considerations: Must distinguish from:
• Sepsis/infection: Fever, tachycardia, hyperventilation resemble salicylate toxicity; salicylate level distinguishes
• Diabetic ketoacidosis: Both present with Kussmaul respirations and anion gap metabolic acidosis; check glucose, ketones, and salicylate level
• Methanol or ethylene glycol poisoning: Similar acid-base picture; specific metabolite testing and osmolar gap assessment differentiate
• Pulmonary embolism: Dyspnea and hyperventilation; imaging and salicylate level differentiate
• Heat stroke: Hyperthermia and altered mental status; history and labs differentiate
• Encephalitis or meningitis: Altered mental status and fever; CSF analysis and salicylate level differentiate

• First-line treatment: Gastrointestinal decontamination
• Activated charcoal (1 g/kg, maximum 50 g): Administer orally if patient is alert and able to protect airway (within 4 hours of ingestion, or longer if bezoar formation suspected). Salicylates bind well to activated charcoal. Multiple-dose activated charcoal (every 4–6 hours) may enhance elimination by interrupting enterohepatic circulation.
• Gastric lavage: Consider if patient presents within 1 hour and has ingested large amount, though evidence for benefit is modest; aspiration risk must be weighed.
• Whole bowel irrigation: Use polyethylene glycol solution (GoLYTELY) if large ingestion or sustained-release preparation suspected; less evidence than in other toxidromes.

• Second-line treatment: Enhanced urinary elimination via alkalinization
• Sodium bicarbonate (most critical intervention for toxicity management): Administer IV sodium bicarbonate to alkalinize urine to pH 7.5–8.5. This is fundamental to treatment.
• Mechanism: Non-ionized (protonated) salicylate at low pH is reabsorbed in renal tubules; ionized salicylate at high pH cannot cross tubular epithelium and is excreted. Alkaline urine increases renal salicylate clearance 10–20 fold.
• Dosing context: Administer 50–100 mEq sodium bicarbonate IV bolus in 500 mL of dextrose-containing fluid, repeated as needed to achieve urine pH >8. Then infuse continuous bicarbonate (150–200 mEq/L in IV fluids) to maintain urine pH. Monitor serum electrolytes, especially hypokalemia, which must be corrected (target K⁺ >3.5 mEq/L) for effective alkalinization.
• Why correct hypokalemia: Acidifying effect of hypokalemia on urine makes alkalinization difficult; potassium reple

Complications of the poisoning itself

• Cerebral neuroglycopenia and cerebral edema (emergency): salicylate uncoupling raises CNS glucose utilization, so brain glucose can be low despite a normal serum glucose. Signaled by confusion, agitation, or seizure with a "normal" fingerstick — the reason empiric IV dextrose is given to any altered salicylate patient.
• Noncardiogenic pulmonary edema / ARDS (emergency): increased pulmonary capillary permeability, not volume overload. Signaled by hypoxemia and diffuse infiltrates with a normal cardiac silhouette; it is a relative contraindication to aggressive bicarbonate fluid loading and, per the EXTRIP workgroup, an indication for hemodialysis.
• Seizures and coma (emergency): acidemia increases the non-ionized fraction crossing the blood–brain barrier; falling pH means rising CNS salicylate even if the serum level plateaus.
• Hyperthermia with rhabdomyolysis (emergency): sustained uncoupling; signaled by core temperature elevation with rising creatine kinase. Antipyretics are useless — the heat is mitochondrial, not prostaglandin-mediated.
• Acute kidney injury: volume depletion plus direct tubular injury; signaled by rising creatinine and oliguria, and it is doubly dangerous because it removes the principal route of elimination once hepatic conjugation is saturated.
• Gastrointestinal hemorrhage: irreversible COX-1 acetylation plus mucosal injury; signaled by hematemesis or melena with a normal platelet count but abnormal platelet function.

Complications of treatment

• Intubation-associated cardiovascular collapse (the classic iatrogenic catastrophe): apnea or a low ventilator minute ventilation abolishes the compensatory respiratory alkalosis, pH plummets, and salicylate floods the CNS. Standard US toxicology teaching, supported by case series associating mechanical ventilation with peri-intubation acidemia and death in salicylate poisoning (Stolbach et al., Academic Emergency Medicine, 2008), cautions against intubation unless unavoidable; if intubated, match or exceed the patient's pre-intubation minute ventilation and bolus bicarbonate peri-procedurally.
• Bicarbonate-induced hypokalemia and hypocalcemia: intracellular potassium shift defeats urinary alkalinization (the kidney trades K⁺ for H⁺); alkalemia lowers ionized calcium and can precipitate tetany or seizure. Signaled by falling serum K⁺ despite repletion, or a positive Chvostek sign.
• Volume overload from alkali infusion: worsens existing pulmonary edema.
• Charcoal aspiration: risk rises with vomiting and depressed mental status — the reason charcoal is withheld from the obtunded patient without a secured airway.

• The acid–base signature is the giveaway: a simultaneous primary respiratory alkalosis and primary anion-gap metabolic acidosis in an adult is salicylate until proven otherwise. Pure DKA or lactic acidosis gives an appropriate respiratory compensation, not a co-existing primary alkalosis. Salicylate is the "S" in MUDPILES.
• Buzzwords that mean salicylate: tinnitus in an elderly patient, oil of wintergreen (methyl salicylate — a teaspoon can be lethal in a toddler because of its extreme concentration), and fever + tachypnea + confusion mistaken for sepsis in a nursing-home patient on chronic aspirin.
• Single best next step in the confused patient: check a fingerstick and give IV dextrose anyway — CNS glucose may be low with a normal serum glucose. Then send a salicylate level, VBG/ABG, and electrolytes, and repeat the level every ~2 hours until it is clearly falling (delayed absorption and bezoar formation make one level useless).
• The association examiners love: urinary alkalinization fails without potassium repletion. Hypokalemia forces the distal tubule to secrete H⁺ in place of K⁺, producing paradoxically acidic urine despite bicarbonate infusion.
• Know the hemodialysis triggers, per the EXTRIP workgroup: altered mental status, pulmonary edema or hypoxemia requiring oxygen, impaired kidney function, refractory acidemia, or a markedly elevated level — dialysis removes both salicylate and the acid load. Impaired kidney function lowers the level at which dialysis is recommended.
• Do not intubate for tachypnea alone. The hyperventilation is the patient's life support; sedation and apnea can be fatal.
• Common distractors to avoid: the Done nomogram is obsolete and should not guide disposition; acetazolamide should be avoided (relatively contraindicated) — it alkalinizes urine only at the cost of worsening systemic acidemia, which increases the non-ionized fraction and drives salicylate into the CNS; antipyretics do not treat uncoupling-mediated hyperthermia; and chronic toxicity can be severe at a level that looks reassuringly "low."